ArticlesEtoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study
Introduction
The shift from non-filter to filter tobacco has resulted in a decrease in small-cell and squamous-cell lung cancer, and an increase in adenocarcinoma of the lung.1 Currently, small-cell lung cancer (SCLC) accounts for 13% of all lung cancer, and about a third of patients with SCLC have limited-stage disease—ie, disease confined to the hemithorax.2
Combination chemotherapy is the cornerstone of SCLC treatment, and meta-analyses3, 4 have shown that addition of thoracic radiotherapy to combination chemotherapy significantly improves the survival of patients with limited-stage SCLC. Several randomised trials5, 6, 7 have shown that early use of concurrent thoracic radiotherapy results in improved overall survival compared with sequential or late use when etoposide and cisplatin are used as combination chemotherapy. The US intergroup phase 3 study8 showed that accelerated hyperfractionated thoracic radiotherapy (AHTRT) with etoposide plus cisplatin for limited-stage SCLC resulted in significantly improved overall survival compared with standard fractionation, once-daily irradiation, with 5-year survival of 26% and 16%, respectively. Thus, etoposide plus cisplatin and AHTRT is now the standard of care in patients with limited-stage SCLC. However, many patients with limited-stage SCLC experience tumour recurrence and die from the disease, showing the need for improved therapy.
The Japan Clinical Oncology Group (JCOG) previously undertook a randomised phase 3 trial9 (JCOG9511) comparing irinotecan plus cisplatin with etoposide plus cisplatin in patients with extensive-stage SCLC. Response and overall survival were significantly better for patients treated with irinotecan than those treated with etoposide. The result prompted us to explore the use of irinotecan and cisplatin in limited-stage SCLC. A phase 2 study10 showed that irinotecan and cisplatin after concurrent etoposide plus cisplatin plus AHTRT for limited-stage SCLC was safe with acceptable side-effects, and the 3-year survival of 38% of patients was encouraging.
Therefore, we did a randomised phase 3 trial to compare overall survival of patients with limited-stage SCLC given three cycles of irinotecan plus cisplatin or etoposide plus cisplatin after one cycle of induction etoposide plus cisplatin and concurrent AHTRT.
Section snippets
Study design and participants
We did this randomised, open-label, phase 3 study in 36 institutions in Japan (appendix). We enrolled patients with histologically or cytologically confirmed limited-stage SCLC—defined as disease confined to one hemithorax, including ipsilateral hilar, bilateral mediastinal, and bilateral supraclavicular lymph node metastases. Pleural effusion of less than 1 cm width by chest CT was defined as limited-stage disease; malignant pleural effusion was defined as extensive-stage disease and excluded
Results
281 patients were enrolled between Sept 1, 2002, and Oct 2, 2006. Four patients were shown to be ineligible after the first registration, three did not receive study treatment because of progressive disease, and two did not receive AHTRT, one because of an inappropriate radiation field and one because of an allergy to etoposide (figure 1). After the induction etoposide plus cisplatin plus AHTRT, 258 patients were enrolled at the second registration and randomised to consolidation etoposide plus
Discussion
In this study of 258 patients with limited-stage SCLC, three cycles of irinotecan plus cisplatin did not improve overall survival compared with three cycles of etoposide plus cisplatin, after one cycle of etoposide plus cisplatin with concurrent AHTRT (panel). Randomisation was done after completion of induction chemoradiotherapy, thus the findings are unlikely to be biased by induction chemoradiotherapy.
JCOG previously reported the results of a randomised phase 3 trial9 (JCOG9511) comparing
References (23)
- et al.
A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease
Ann Oncol
(2010) - et al.
A meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer
J Thorac Oncol
(2010) - et al.
Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis
J Thorac Oncol
(2010) - et al.
Medical Research Council comparative trial of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus. Ten-year follow-up
Lancet
(1973) - et al.
Nonfilter and filter cigarette consumption and the incidence of lung cancer by histological type in Japan and the United States: analysis of 30-year data from population-based cancer registries
Int J Cancer
(2011) - et al.
Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database
J Clin Oncol
(2006) - et al.
A meta-analysis of thoracic radiotherapy for small-cell lung cancer
N Engl J Med
(1992) - et al.
Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis
J Clin Oncol
(1992) - et al.
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer
J Clin Oncol
(1993) - et al.
Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study
J Clin Oncol
(1997)